Savant Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Savant Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$58.6K	Buy	+47,646	New	+$76.1K	﹤0.01%	2372

Other funds holding ALDX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 22.25% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Providence Wealth Advisors Frankfort, Illinois $174M AUM 29.13% 1-Year Est. Return

Hikari Power Tokyo, Japan $439M AUM 11.38% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Letko, Brosseau & Associates Montreal, Quebec, Canada $6.9B AUM 29.83% 1-Year Est. Return

Savant Capital's ALDX Position: Q3 2026 in Review

Savant Capital opened a new position in Aldeyra Therapeutics (ALDX) in Q3 2026: 47,646 shares worth $58.6K. The stake represents ﹤0.01% of the portfolio and ranks #2372 among its holdings.

28 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

Savant Capital held 47,646 shares of Aldeyra Therapeutics worth $58.6K as of Q3 2026.
Aldeyra Therapeutics was a new Savant Capital position in Q3 2026.
Aldeyra Therapeutics made up ﹤0.01% of Savant Capital's portfolio in Q3 2026, its #2372 holding.
28 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on Savant Capital's 13F filing for Q3 2026, filed 6 Nov 2026.